Business Context and Reporting Period
This Form 8-K was filed by Veeva Systems Inc. on January 15, 2014. The report addresses public statements regarding the company's relationship with Genentech, Inc., a member of the Roche Group.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It references previously provided financial results and guidance but does not restate them in this document.
Material Changes and Events
- Contract Expiration: The subscription agreement between Veeva and Genentech for the use of Veeva CRM in the United States expired during Veeva's fiscal second quarter ended July 31, 2013.
- Financial Impact: The financial impact of this expiration is already reflected in previously reported results and guidance.
- Customer Concentration: Genentech was not one of Veeva's top 20 customers by revenue in any of the last eight completed fiscal quarters.
Management Commentary and Outlook
Management states that the circumstances leading to the expiration of the Genentech agreement are specific to that relationship and are not indicative of a broader trend among Veeva's customer base. The company does not believe this event signals a general deterioration in customer retention.
Key Facts for Investor Verification
- Confirm that the financial impact of the Genentech contract expiration is fully captured in prior quarterly reports.
- Verify the current status of Veeva's top 20 customer list to ensure no other significant contracts are at risk.
- Review subsequent earnings releases to confirm that the "no trend" assertion holds true in the quarters following this filing.